Kezar Life Sciences (FRA:2KZ) Total Stockholders Equity : €155.59 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences Total Stockholders Equity?

Kezar Life Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €155.59 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Kezar Life Sciences's Book Value per Share for the quarter that ended in Mar. 2024 was €2.14. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Kezar Life Sciences's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.11.

Kezar Life Sciences Total Stockholders Equity Historical Data

The historical data trend for Kezar Life Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences Total Stockholders Equity Chart

Kezar Life Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

70.24

115.88

174.24

254.76

172.00

Kezar Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															235.83	214.39	202.39	172.00	155.59

Kezar Life Sciences (FRA:2KZ) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Kezar Life Sciences's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(155.591	-	0)	/	72.8014
	=	2.14

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Kezar Life Sciences's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.083	+	12.74)	/	155.591
	=	0.11

Kezar Life Sciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kezar Life Sciences (FRA:2KZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (FRA:2KZ) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

KZR:USA 2KZ:Germany

Address

4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.kezarlifesciences.com

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Kezar Life Sciences (FRA:2KZ) Headlines

No Headlines